These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34973409)

  • 1. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen.
    Cámara-Martinez I; Blechar JA; Ruiz-Picazo A; Garcia-Arieta A; Calandria C; Merino-Sanjuan V; Langguth P; Gonzalez-Alvarez M; Bermejo M; Al-Gousous J; Gonzalez-Alvarez I
    Int J Pharm; 2022 Feb; 614():121415. PubMed ID: 34973409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
    Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
    Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution of a Biopharmaceutics Classification System Class II Free Acid from Immediate Release Tablets Containing a Microenvironmental pH Modulator: Comparison of a Biorelevant Bicarbonate Buffering System with Phosphate Buffers.
    Haznar-Garbacz D; Hoc D; Garbacz G; Lachman M; Słomińska D; Romański M
    AAPS PharmSciTech; 2022 Jul; 23(6):203. PubMed ID: 35882674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.
    Koenigsknecht MJ; Baker JR; Wen B; Frances A; Zhang H; Yu A; Zhao T; Tsume Y; Pai MP; Bleske BE; Zhang X; Lionberger R; Lee A; Amidon GL; Hasler WL; Sun D
    Mol Pharm; 2017 Dec; 14(12):4295-4304. PubMed ID: 28937221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation on the possibility of biowaivers for ibuprofen.
    Alvarez C; Núñez I; Torrado JJ; Gordon J; Potthast H; García-Arieta A
    J Pharm Sci; 2011 Jun; 100(6):2343-9. PubMed ID: 21491448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs.
    Hens B; Tsume Y; Bermejo M; Paixao P; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Loebenberg R; Lee A; Frances A; Amidon G; Yu A; Benninghoff G; Salehi N; Talattof A; Sun D; Amidon GL
    Mol Pharm; 2017 Dec; 14(12):4281-4294. PubMed ID: 28737409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating a Modified Apparatus to Discriminate the Dissolution Capacity In Vitro and Establish an IVIVC of Mycophenolate Mofetil Tablets in the Fed State.
    Zhang G; Sun M; Jiang S; Wang L; Tan Y; Wang L; Cheng Z
    J Pharm Sci; 2021 Mar; 110(3):1240-1247. PubMed ID: 33096138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FaSSIF-V3, but not compendial media, appropriately detects differences in the peak and extent of exposure between reference and test formulations of ibuprofen.
    Cristofoletti R; Dressman JB
    Eur J Pharm Biopharm; 2016 Aug; 105():134-40. PubMed ID: 27287554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution Methods to Increasing Discriminatory Power of In Vitro Dissolution Testing for Ibuprofen Free Acid and Its Salts.
    Cristofoletti R; Dressman JB
    J Pharm Sci; 2017 Jan; 106(1):92-99. PubMed ID: 27397434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers.
    Lake OA; Olling M; Barends DM
    Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
    Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
    Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possibility of extending biopharmaceutics classification system based biowaiver to BCS class IIa drug.
    Khalid F; Hassan SMF; Noor R; Zaheer K; Hassan F
    Pak J Pharm Sci; 2019 Sep; 32(5):2065-2073. PubMed ID: 31813872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets.
    Garcia-Arieta A; Gordon J; Gwaza L; Mangas-Sanjuan V; Álvarez C; Torrado JJ
    Mol Pharm; 2015 Sep; 12(9):3194-201. PubMed ID: 26237401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study.
    Wang J; Chen J; Wang L; Yang D; Shao R; Lou H; Ruan Z; Jiang B
    Clin Transl Sci; 2023 Jan; 16(1):85-91. PubMed ID: 36178248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel.
    Salehi N; Al-Gousous J; Mudie DM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2020 Oct; 17(10):3870-3884. PubMed ID: 32886520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions.
    Bermejo M; Paixão P; Hens B; Tsume Y; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Löbenberg R; Lee A; Frances A; Amidon GE; Yu A; Salehi N; Talattof A; Benninghoff G; Sun D; Kuminek G; Cavanagh KL; Rodríguez-Hornedo N; Amidon GL
    Mol Pharm; 2018 Dec; 15(12):5454-5467. PubMed ID: 30372084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.
    Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M
    Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Novel Gastric Process Simulation Model: The Successful Assessment of Bioequivalence and Bioinequivalence of a Biopharmaceutics Classification System Class II Weak Acid Drug.
    Zenda N; Tagami T; Ozeki T
    Biol Pharm Bull; 2022; 45(3):364-373. PubMed ID: 35228402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.